Suppr超能文献

Preliminary study on proteomics of gastric carcinoma and its clinical significance.

作者信息

Qian Hong-Gang, Shen Jing, Ma Hong, Ma Hua-Chong, Su Ya-Hui, Hao Chun-Yi, Xing Bao-Cai, Huang Xin-Fu, Shou Cheng-Chao

机构信息

Department of Surgery, Peking University School of Clinical Oncology, Beijing Cancer Hospital, Haidian District, Beijing 100036, China.

出版信息

World J Gastroenterol. 2005 Oct 28;11(40):6249-53. doi: 10.3748/wjg.v11.i40.6249.

Abstract

AIM

To explore the preliminary identification of serum protein pattern models that may be novel potential biomarkers in the detection of gastric cancer.

METHODS

A total of 130 serum samples, including 70 from patients with gastric cancer and 60 from healthy adults, were detected by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS). The data of spectra were analyzed by Biomarker Patterns Software (BPS). Thirty serum samples of gastric cancer patients and 30 serum samples of healthy adults were grouped into the training group to build models, and the other 70 samples were used to test and evaluate the models. The samples of the test group were judged only with their peaks' height and were separated into cancer group or healthy control group by BPS automatically and the judgments were checked with the histopathologic diagnosis of the samples.

RESULTS

Sixteen mass peaks were found to be potential biomarkers with a significant level of P< 0.01. Among them, nine mass peaks showed increased expression in patients with gastric cancer. Analyzed by BPS, two peaks were chosen to build the model for gastric cancer detection. The sensitivity, specificity, and accuracy of the model were 90%, 36/40, 86.7%, 26/30, and 88.6%, 62/70, respectively, which were greatly higher than those of clinically used serum biomarkers CEA (carcinoembryonic antigen), CA19-9 and CA72-4. Stage I/II gastric cancer samples of the test group were all judged correctly.

CONCLUSION

The novel biomarkers in serum and the established model could be potentially used in the detection of gastric cancer. However, large-scale studies should be carried on to further explore the clinical impact on the model.

摘要

相似文献

1
Preliminary study on proteomics of gastric carcinoma and its clinical significance.
World J Gastroenterol. 2005 Oct 28;11(40):6249-53. doi: 10.3748/wjg.v11.i40.6249.
2
Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer.
Jpn J Clin Oncol. 2010 Apr;40(4):336-42. doi: 10.1093/jjco/hyp175. Epub 2010 Jan 20.
3
Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS.
Mol Med Rep. 2012 Jun;5(6):1531-5. doi: 10.3892/mmr.2012.834. Epub 2012 Mar 13.
5
Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
BMC Cancer. 2005 Jul 20;5:83. doi: 10.1186/1471-2407-5-83.
6
Detection of hypopharyngeal squamous cell carcinoma using serum proteomics.
Acta Otolaryngol. 2006 Aug;126(8):853-60. doi: 10.1080/00016480500525205.
7
Diagnosis of gastric cancer using decision tree classification of mass spectral data.
Cancer Sci. 2007 Jan;98(1):37-43. doi: 10.1111/j.1349-7006.2006.00339.x.
10
Mining novel biomarkers for prognosis of gastric cancer with serum proteomics.
J Exp Clin Cancer Res. 2009 Sep 9;28(1):126. doi: 10.1186/1756-9966-28-126.

引用本文的文献

1
Diagnostic and prognostic role of serum protein peak at 6449 m/z in gastric adenocarcinoma based on mass spectrometry.
Br J Cancer. 2016 Apr 12;114(8):929-38. doi: 10.1038/bjc.2016.52. Epub 2016 Mar 22.
2
Emerging blood-based biomarkers for detection of gastric cancer.
World J Gastroenterol. 2015 Nov 7;21(41):11636-53. doi: 10.3748/wjg.v21.i41.11636.
3
Proteomic and metabolic prediction of response to therapy in gastric cancer.
World J Gastroenterol. 2014 Oct 14;20(38):13648-57. doi: 10.3748/wjg.v20.i38.13648.
4
Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.
Nat Clin Pract Gastroenterol Hepatol. 2009 Mar;6(3):170-83. doi: 10.1038/ncpgasthep1366.
6
Applications of SELDI-MS technology in oncology.
J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47. doi: 10.1111/j.1582-4934.2008.00250.x. Epub 2008 Feb 4.
7
Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.
J Chromatogr A. 2007 Jun 15;1153(1-2):259-76. doi: 10.1016/j.chroma.2006.11.054. Epub 2006 Dec 12.
8
Human body fluid proteome analysis.
Proteomics. 2006 Dec;6(23):6326-53. doi: 10.1002/pmic.200600284.

本文引用的文献

1
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer.
Curr Opin Biotechnol. 2004 Feb;15(1):24-30. doi: 10.1016/j.copbio.2004.01.005.
2
Detection of tumor markers with ProteinChip technology.
Curr Pharm Biotechnol. 2004 Feb;5(1):45-67. doi: 10.2174/1389201043489675.
6
Use of proteomic analysis to monitor responses to biological therapies.
Expert Opin Biol Ther. 2004 Jan;4(1):83-93. doi: 10.1517/14712598.4.1.83.
7
Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry.
Kidney Int. 2004 Jan;65(1):323-32. doi: 10.1111/j.1523-1755.2004.00352.x.
8
Current developments in SELDI affinity technology.
Mass Spectrom Rev. 2004 Jan-Feb;23(1):34-44. doi: 10.1002/mas.10066.
10
Magnetic resonance image-guided proteomics of human glioblastoma multiforme.
J Magn Reson Imaging. 2003 Nov;18(5):530-6. doi: 10.1002/jmri.10395.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验